Prevention of hepatitis B with the hepatitis B vaccine

New England Journal of Medicine

Volumn 351, Issue 27, 2004, Pages 2832-2838

  Poland, Gregory A ^a   Jacobson, Robert M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN;

AUTOIMMUNE DISEASE; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL; DEMYELINATING DISEASE; DIABETES MELLITUS; DISEASE TRANSMISSION; HEPATITIS B; HUMAN; NURSE; OPTIC NERVE DISEASE; PRENATAL CARE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; VACCINATION; ADULT; BLOOD; FEMALE; HEPATITIS B VIRUS; IMMUNOLOGY; MALE; NEWBORN; PRACTICE GUIDELINE; PREGNANCY;

ADULT; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULINS; INFANT, NEWBORN; MALE; PRACTICE GUIDELINES; PREGNANCY;

EID: 16544365632     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMcp041507     Document Type: Review

References (42)

1. Hsieh CC, Tzonou A, Zavitsanos X, Kaklamani E, Lan SJ, Trichopoulos D. Age at first establishment of chronic hepatitis B virus infection and hepatocellular carcinoma risk: a birth order study. Am J Epidemiol 1992;136:1115-21.
2. Zuckerman AJ. Prevention of primary liver cancer by immunization. N Engl J Med 1997;336:1906-7.
3. Incidence of acute hepatitis B - United States, 1990-2002. MMWR Morb Mortal Wkly Rep 2004;52:1252-4.
4. Meheus A. Teenagers' lifestyle and the risk of exposure to hepatitis B virus. Vaccine 2000;18:Suppl 1:S26-S29.
5. Beasley RP, Stevens CE, Shiao IS, Meng HC. Evidence against breast-feeding as a mechanism forvertical transmission of hepatitis B. Lancet 1975;2:740-1.
6. Patrick DM, Bigham M, Ng H, White R, Tweed A, Skowronski DM. Elimination of acute hepatitis B among adolescents after one decade of an immunization program targeting Grade 6 students. Pediatr Infect Dis J 2003;22:874-7.
7. Duclos P. Safety of immunisation and adverse events following vaccination against hepatitis B. Expert Opin Drug Saf 2003;2:225-31.
8. Global progress toward universal childhood hepatitis B vaccination, 2003. MMWR Morb Mortal Wkly Rep 2003;52:868-70.
9. Hall A, Kane M, Roure C, Meheus A. Multiple sclerosis and hepatitis B vaccine? Vaccine 1999;17:2473-5.
10. Chang M-H, Chen C-J, Lai M-S, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997;336:1855-9.
11. Hsu H-M, Chen D-S, Chuang C-H, et al. Efficacy of a mass hepatitis B vaccination program in Taiwan: studies on 3464 infants of hepatitis B surface antigen-carrier mothers. JAMA 1988;260:2231-5.
12. Chen H-L, Chang M-H, Ni Y-H, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 1996;276:906-8.
13. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991;40(RR-13):1-25.
14. Lindsay KL, Herbert DA, Gitnick GL. Hepatitis B vaccine: low postvaccination immunity in hospital personnel given gluteal injections. Hepatology 1985;5:1088-90.
15. Suboptimal response to hepatitis B vaccine given by injection into the buttock. MMWR Morb Mortal Wkly Rep 1985;34:105-8, 113.
16. Lemon SM, Weber DJ. Immunogenicity of plasma-derived hepatitis B vaccine: relationship to site of injection and obesity. J Gen Intern Med 1986;11:199-201.
17. Shaw FE Jr, Guess HA, Roets JM, et al. Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. Vaccine 1989;7:425-30.
18. Poland GA, Borrud A, Jacobson RM, et al. Determination of deltoid fat pad thickness: implications for needle length in adult immunization. JAMA 1997;277:1709-11.
19. Coleman PJ, Shaw FE Jr, Serovich J, Hadler SC, Margolis HS. Intradermal hepatitis B vaccination in a large hospital employee population. Vaccine 1991;9:723-7.
20. Das HS, Sawant P, Shirhatti RG, et al. Efficacy of low dose intradermal hepatitis B vaccine: results of a randomized trial among health care workers. Trop Gastroenterol 2002;23:120-1.
21. FDA approval for a combined hepatitis A and B vaccine. MMWR Morb Mortal Wkly Rep 2001;50:806-7.
22. Fisman DN, Agrawal D, Leder K. The effect of age on immunologie response to recombinant hepatitis B vaccine: a meta-analysis. Clin Infect Dis 2002;35:1368-75.
23. Mast E, Mahoney F, Kane M, Margolis H. Hepatitis B vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines. Philadelphia: Saunders, 2004:299-337.
24. Poland GA. Hepatitis B immunization in health care workers: dealing with vaccine nonresponse. Am J Prev Med 1998;15:73-7.
25. Wainwright RB, McMahon BJ, Bulkow LR, Parkinson AJ, Harpster AP, Hadler SC. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population - preliminary results of an 8-year study. In: Hollinger FB, Lemon SM, Margolis H, eds. Viral hepatitis and liver disease: proceedings of the 1990 International Symposium on Viral Hepatitis and Liver Disease. Baltimore: Williams & Wilkins, 1991:762-6.
26. Hadler SC, Coleman PJ, O'Malley P, Judson FN, Altman N. Evaluation of long-term protection by hepatitis B vaccine for seven to nine years in homosexual men. In: Hollinger FB, Lemon SM, Margolis H, eds. Viral hepatitis and liver disease: proceedings of the 1990 International Symposium on Viral Hepatitis and Liver Disease. Baltimore: Williams & Wilkins, 1991:766-8.
27. McMahnon BJ, Wainwright RB. Protective efficacy of hepatitis B vaccines in infants, children, and adults. In: Ellis RW, ed. Hepatitis B vaccines in clinical practice. New York: Marcel Dekker, 1993:243-61.
28. Wainwright RB, McMahon BJ, Bulkow LR, et al. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population. JAMA 1989;261:2362-6.
29. Hadler SC, Judson PM, O'Malley NL, et al. Studies of hepatitis B vaccine in homosexual men. In: Coursaget P, Tong MJ, eds. Progress in hepatitis B immunization. London: Colloque Inserm/John Libbey Eurotext, 1990:165-75.
30. Wainwright RB, McMahon BJ, Bulkow LR, Parkinson AJ, Harpster AP. Protection provided by hepatitis B vaccine in a Yupik Eskimo population: seven-year results. Arch Intern Med 1991;151:1634-6.
31. DeStefano F, Verstraeten T, Jackson LA, et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol 2003;60:504-9.
32. Confavreux C, Suissa S, Saddier P, et al. Vaccinations and the risk of relapse in multiple sclerosis. N Engl J Med 2001;344:319-26.
33. Expanded Programme on Immunization (EPI): lack of evidence that hepatitis B vaccine causes multiple sclerosis. Wkly Epidemiol Rec 1997;72:149-52.
34. Ascherio A, Zhang SM, Hernán MA, et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 2001;344:327-32.
35. Global Advisory Committee on Vaccine Safety, 20-21 June 2002. Wkly Epidemiol Rec 2002;77:389-94.
36. Stratton K, Almario DA, McCormick MC, eds. Immunization safety review: hepatitis B vaccine and demyelinating neurological disorders. Washington, D.C.: National Academies Press, 2002.
37. Gall SA. Maternal immunization. Obstet Gynecol Clin North Am 2003;30:623-36.
38. Averhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E, Margolis H. Immunogenicity of hepatitis B vaccines: implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 1998;15:1-8.
39. Wilson JN, Nokes DJ, Carman WF. The predicted pattern of emergence of vaccine-resistant hepatitis B: a cause for concern? Vaccine 1999;17:973-8.
40. 2 particles for revaccination of healthy adult nonresponders. J Infect Dis 1997;175:678-81.
41. Heineman TC, Clements-Mann ML, Poland GA, et al. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine 1999;17:2769-78.
42. Rottinghaus ST, Poland GA, Jacobson RM, Barr LJ, Roy MJ. Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination. Vaccine 2003;21:4604-8.